UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For Quarter ended March 31, 1997 Commission file number: 1-3285
MINNESOTA MINING AND MANUFACTURING COMPANY
State of Incorporation: Delaware
I.R.S. Employer Identification No. 41-0417775
Executive offices: 3M Center, St. Paul, Minnesota 55144
Telephone number: (612) 733-1110
Indicate by check mark whether the Registrant (1) has
filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90
days. Yes X . No .
On March 31, 1997, there were 416,244,474 shares of the
Registrant's common stock outstanding.
This document contains 23 pages.
The exhibit index is set forth on page 19.
Minnesota Mining and Manufacturing Company and Subsidiaries
PART I. Financial Information
Consolidated Statement of Income
(Amounts in millions, except per-share amounts)
(Unaudited)
Three months ended
March 31
1997 1996
Net sales $3,714 $3,468
Operating expenses
Cost of goods sold 2,089 1,990
Selling, general and
administrative expenses 937 882
Total 3,026 2,872
Operating income 688 596
Other income and expense
Interest expense 23 17
Investment and other
income - net (12) (19)
Total 11 (2)
Income before income taxes
and minority interest 677 598
Provision for income taxes 244 218
Minority interest 23 18
Net income $ 410 $ 362
Average shares outstanding 416.6 418.5
Per-share amounts
Net income $ .99 $ .87
Cash dividends declared
and paid $ .53 $ .47
The accompanying Notes to Consolidated Financial Statements
are an integral part of this statement.
Minnesota Mining and Manufacturing Company and Subsidiaries
Consolidated Balance Sheet
(Dollars in millions)
March 31,
Assets 1997 December 31,
Current assets (Unaudited) 1996
Cash and cash equivalents $ 373 $ 583
Other securities 163 161
Accounts receivable - net 2,612 2,504
Inventories
Finished goods 1,201 1,195
Work in process 614 591
Raw materials and supplies 489 478
Total inventories 2,304 2,264
Other current assets 985 974
Total current assets 6,437 6,486
Investments 597 585
Property, plant and equipment 11,985 12,050
Less accumulated depreciation (7,159) (7,206)
Property, plant and equipment - net 4,826 4,844
Other assets 1,436 1,449
Total $13,296 $13,364
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable $ 887 $ 895
Payroll 312 300
Income taxes 247 201
Short-term debt 1,151 1,117
Other current liabilities 1,088 1,093
Total current liabilities 3,685 3,606
Other liabilities 2,544 2,623
Long-term debt 831 851
Stockholders' equity
Common stock, no par, 472,016,528 shares issued 296 296
Retained earnings 8,921 8,756
Unearned compensation - ESOP (405) (412)
Cumulative translation - net (334) (178)
Debt & equity securities, unrealized gain - net 8 15
Treasury stock, at cost
March 31, 1997, 55,772,054 shares;
December 31, 1996, 55,180,520 shares (2,250) (2,193)
Stockholders' equity - net 6,236 6,284
Total $13,296 $13,364
The accompanying Notes to Consolidated Financial Statements
are an integral part of this statement.
Minnesota Mining and Manufacturing Company and Subsidiaries
Consolidated Statement of Cash Flows
(Dollars in millions)
(Unaudited)
Three months ended
March 31
1997 1996
Cash Flows from Operating Activities
Net income $ 410 $ 362
Adjustments to reconcile net income
to net cash provided by operating activities
Implant litigation - net (19) (156)
Depreciation and amortization 217 217
Working capital and other changes (171) (15)
Net cash provided by continuing operations 437 408
Net cash (used) provided by discontinued operations (55) 108
Net cash provided by operating activities 382 516
Cash Flows from Investing Activities
Capital expenditures (296) (232)
Other changes - net (2) 5
Discontinued operations - net -- (37)
Net cash used in investing activities (298) (264)
Cash Flows from Financing Activities
Change in short-term debt - net 258 (5)
Repayment of long-term debt (219) (1)
Proceeds from long-term debt 6 --
Purchases of treasury stock (249) (112)
Reissuances of treasury stock 119 75
Payment of dividends (221) (197)
Net cash used in financing activities (306) (240)
Effect of exchange rate changes on cash 12 30
Net (decrease) increase in cash and cash equivalents (210) 42
Cash and cash equivalents at beginning of year 583 485
Cash and cash equivalents at end of period $ 373 $ 527
The accompanying Notes to Consolidated Financial Statements
are an integral part of this statement.
Minnesota Mining and Manufacturing Company and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
The interim financial statements are unaudited but, in the opinion of
management, reflect all adjustments necessary for a fair presentation
of financial position, results of operations and cash flows for the
periods presented. These adjustments consist of normal, recurring
items. The results of operations for any interim period are not
necessarily indicative of results for the full year. The condensed
consolidated financial statements and notes are presented as
permitted by the requirements for Form 10-Q and do not contain
certain information included in the company's annual consolidated
financial statements and notes. This Form 10-Q should be read in
conjunction with the company's consolidated financial statements and
notes included in its 1996 Annual Report on Form 10-K.
Earnings per share:
In February 1997, the Financial Accounting Standards Board issued
Statement No. 128, "Earnings Per Share." This statement establishes
standards for computing and presenting basic and diluted earnings per
share (EPS) for financial statements issued for periods ending after
December 15, 1997. The adoption of this statement will not have a
material effect on the company's reported EPS.
Reclassification:
Certain reclassifications have been made to December 31, 1996,
balance sheet amounts to conform with the current year presentation.
Other:
Discussion of legal matters is cross-referenced to this Form 10-Q,
Part II, Item 1, Legal Proceedings, and should be considered an
integral part of the Consolidated Financial Statements and Notes.
Coopers & Lybrand L.L.P., the company's independent auditors, have
performed a review of the unaudited interim financial statements
included herein and their report thereon accompanies this filing.
Report of Independent Auditors
To the Stockholders of Minnesota Mining and Manufacturing Company:
We have reviewed the accompanying condensed consolidated balance
sheet of Minnesota Mining and Manufacturing Company and Subsidiaries
as of March 31, 1997, and the related condensed consolidated
statements of income and cash flows for the three-month periods ended
March 31, 1997 and 1996. These financial statements are the
responsibility of the Company's management.
We conducted our reviews in accordance with standards established by
the American Institute of Certified Public Accountants. A review of
interim financial information consists principally of applying
analytical procedures to financial data and making inquiries of
persons responsible for financial and accounting matters. It is
substantially less in scope than an audit conducted in accordance
with generally accepted auditing standards, the objective of which is
the expression of an opinion regarding the financial statements taken
as a whole. Accordingly, we do not express such an opinion.
Based on our reviews, we are not aware of any material modifications
that should be made to the condensed consolidated financial
statements referred to above for them to be in conformity with
generally accepted accounting principles.
We have previously audited, in accordance with generally accepted
auditing standards, the consolidated balance sheet as of December 31,
1996, and the related consolidated statements of income and cash
flows for the year then ended (not presented herein); and in our
report dated February 10, 1997, we expressed an unqualified opinion
on those consolidated financial statements. In our opinion, the
information set forth in the accompanying condensed consolidated
balance sheet as of December 31, 1996, is fairly stated in all
material respects in relation to the consolidated balance sheet from
which it has been derived.
/s/ COOPERS & LYBRAND L.L.P.
COOPERS & LYBRAND L.L.P.
St. Paul, Minnesota
April 22, 1997
Minnesota Mining and Manufacturing Company and Subsidiaries
Management's Discussion and Analysis of
Financial Condition and Results of Operations
RESULTS OF OPERATIONS
First Quarter
Worldwide sales for the first quarter totaled $3.714 billion, an
increase of 7.1 percent from the first quarter last year. Excluding
changes in currency exchange rates, sales rose about 11 percent.
Unit sales increased about 11 percent, while selling prices were down
slightly. The company posted double-digit volume gains in its two
business sectors, and in U.S. and international operations.
In the Life Sciences Sector, sales increased about 11 percent in
local currencies. Pacing this revenue growth were the sector's
medical, pharmaceuticals, commercial graphics, and safety and
security businesses.
In the Industrial and Consumer Sector, sales increased about 11
percent in local currencies. This sector registered strong increases
in tapes, abrasives, specialty chemicals, office supplies and other
major product lines.
In the United States, sales were up about 12 percent to $1.759
billion, driven by increases in volume. Selling prices in the United
States were flat.
Internationally, sales totaled $1.955 billion. Volume increased
about 11 percent and selling prices were down about 1 percent.
Currency translation reduced international sales by about 7 percent.
3M companies in the Asia Pacific area and in Latin America led the
way. In the Asia Pacific area, volume increased more than 15
percent, with strong gains both in Japan and in the Asia region. In
Latin America, volume rose nearly 20 percent, continuing that
region's record of healthy gains. In Europe, volume was up nearly 7
percent, despite continued softness in Germany. Among larger
companies there, France and Italy posted good gains. Worldwide, this
was the third consecutive quarter in which the company has posted
double-digit volume growth.
Cost of goods sold, which includes manufacturing, research and
development, and engineering, was 56.3 percent of sales, down more
than one percentage point from the first quarter last year. Cost of
goods sold as a percent of sales benefited from volume, productivity
and from a positive carryover on raw material costs. Changes in
currency exchange rates reduced gross margins by about four-tenths of
a percentage point. This effect relates to the purchases made by
3M's international companies from the United States.
Selling, general and administrative spending was 25.2 percent of
sales, down two-tenths of a point from the same quarter last year.
Operating income was $688 million, up 15.6 percent from the first
quarter last year. Currency reduced operating income by about $37
million, or about 6 percent. In the United States, operating income
was 17.7 percent of sales, up more than three percentage points from
the same quarter last year, and in line with the level averaged in
each of the past three quarters. U.S. profits increased more than 30
percent from the first quarter last year. Internationally, operating
income was 19.3 percent of sales, down slightly from the same quarter
last year. International profits rose about 2 percent in dollars and
12 percent in local currencies. Worldwide operating income was 18.5
percent of sales, up 1.3 points from the first quarter last year, and
up a full point from 1996 in total. Profit growth and margin
improvement were led by the Industrial and Consumer Sector.
First quarter interest expense of $23 million was up $6 million from
the same quarter last year. Net investment and other income was $12
million, down $7 million from the first quarter last year. This
total of $11 million for first quarter of 1997 is a typical quarterly
rate. In the first quarter last year other income and expense
benefited from some non-recurring items.
The worldwide effective income tax rate was 36.0 percent in the first
quarter of 1997, down slightly from 36.5 percent in the first quarter
of 1996.
Net income totaled $410 million, or $.99 per share, with per-share
income up 13.8 percent from the first quarter of 1996. The company
estimates that changes in the value of the U.S. dollar decreased
earnings for the quarter by about 5 cents per share compared with the
first quarter of 1996. This estimate includes the effect of
translating profits from local currencies into U.S. dollars, the
costs in local currencies of transferring goods between the parent
company in the United States and international companies, and
transaction gains and losses in countries not considered to be highly
inflationary.
As discussed in this Form 10-Q, Part II, Item 1, Legal Proceedings,
mammary implant litigation resulted in a pre-tax charge of $35
million ($22 million after tax) in the first quarter of 1994. There
can be no certainty that the company may not ultimately incur
charges, whether for governmental proceedings and claims, products
liability claims, environmental proceedings or other actions, in
excess of presently established accruals. While such future charges
could have a material adverse impact on the company's net income in
the quarterly period in which they are recorded, the company believes
that such additional charges, if any, would not have a material
adverse effect on the consolidated financial position or annual
results of operations of the company.
FUTURE OUTLOOK
3M expects solid sales and earnings growth in 1997. The company
expects to benefit from major new product programs, intensified
customer satisfaction efforts, on-going productivity improvement,
further expansion into international markets, and efforts to
streamline 3M's supply chain.
While volume and productivity are expected to help 1997 results,
currency effects will moderate profit growth. Based on current
exchange rates, currency effects could reduce earnings by an amount
approaching 25 cents a share for all of 1997. Raw material costs are
expected to be down slightly for 1997 as a whole.
For the year 1997, capital spending is expected to total about $1.3
billion. The company is investing capital to help sustain top-line
growth and to improve productivity.
FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe
harbor for certain forward-looking statements. This Quarterly Report
on Form 10-Q contains forward-looking statements that reflect the
company's current views with respect to future events and financial
performance.
These forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially
from historical results or those anticipated. The words "aim,"
"believe," "expect," "anticipate," "intend," "estimate" and other
expressions that indicate future events and trends identify forward-
looking statements. Actual future results and trends may differ
materially from historical results or those anticipated depending on
a variety of factors, including, but not limited to, foreign exchange
rates and fluctuations in those rates; the effects of, and changes
in, worldwide economic conditions; raw materials, including shortages
and increases in the costs of key raw materials; and legal
proceedings (see discussion of Legal Proceedings in Part II, Item 1
of this Form 10-Q).
FINANCIAL CONDITION AND LIQUIDITY
The company's financial condition and liquidity remain strong.
Working capital decreased $128 million to $2.752 billion from $2.880
billion as of December 31, 1996. The accounts receivable average
days' sales outstanding was 56 days, down 4 days from year-end 1996.
The company's key inventory index, which represents the number of
months of inventory on hand, was unchanged from year-end, and is now
at 3.8 months. The company's current ratio was 1.7, essentially
unchanged from year-end.
Total debt increased $14 million from year-end 1996 to $1.982
billion. Current maturities of long-term debt are anticipated to be
funded through new debt issuances. On April 7, 1997, subsequent to
the end of the first quarter, the company issued a four-year $250
million 6.625 percent Eurobond. After giving effect to an interest
rate swap effected on the same date for the same term as the
Eurobond, the company will have an interest obligation based on a
floating LIBOR index.
The company's borrowings continue to maintain AAA long-term ratings.
As of March 31, 1997, total debt was 24 percent of total capital.
Return on average stockholders' equity for the first three months was
26.2 percent, exceeding the company's goal of 20 to 25 percent.
Return on capital employed for the first three months was 26.7
percent, up from 24.5 percent in the comparable 1996 period. The
company's goal is 27 percent or better.
Net cash provided by operating activities from continuing operations
totaled $437 million in the first three months of the year, up $29
million from the same period last year. First quarter 1997 cash flow
supported increased working capital needs related to double-digit
volume growth, while 1996 had an incremental $137 million net cash
outflow related to mammary implant litigation compared to 1997.
Net cash used by operating activities from discontinued operations
was $55 million in the first three months compared with $108 million
of cash provided in the same period last year. During 1996 the
company generated cash from discontinued operations by liquidating
audio/video assets and operating Imation's businesses before spin-
off. Payments made in 1997 primarily reflect severance payments
related to discontinued operations.
Timing differences between payment of implant liabilities and receipt
of related insurance recoveries could affect the cash flows of future
periods. The amount and timing of prospective payments and receipts
cannot be determined with precision at this time. In January 1996,
the company paid $130 million into a court-administered fund as an
initial reserve against costs of claims payable by the company under
the "Revised Settlement Program," which is discussed in the legal
proceedings section in Part II, Item 1, of this Form 10-Q.
Cash used in investing activities was $298 million in the first three
months of the year, up $34 million from the same period last year.
Capital expenditures for the first three months of 1997 were $296
million, an increase of about 28 percent compared with the same
period last year, and up about 7 percent compared to an average
quarter in 1996.
Financing activities for both short-term and long-term debt provided
net cash inflows of $45 million, compared with outflows of $6 million
in the first three months last year. Treasury stock repurchases were
$249 million, compared with repurchases in the same period last year
of $112 million.
The company repurchased about 2.9 million shares of common stock in
the first three months of this year, compared with 1.7 million shares
in the same period last year. In November 1996, the Board of
Directors authorized the repurchase of up to 10 million shares of 3M
common stock through December 31, 1997. As of March 31, 1997, 5.8
million shares remained authorized for repurchase. Stock repurchases
are made to support employee stock purchase plans and for other
corporate purposes.
Dividends paid increased over 12%. Payments totaled $221 million in
the first three months of this year, compared with $197 million in
the same period last year. In February 1997, the quarterly dividend
was increased to 53 cents a share, compared to 47 cents a share in
the first quarter last year.
3M maintains a shelf registration with the Securities and Exchange
Commission that provides the means to offer medium-term notes not to
exceed $601 million. As of March 31, 1997, $402 million of the shelf
registration was available for future financial needs. The company
expects cash generated by operating activities will support its
primary growth initiatives, with ample borrowing capacity and lines
of credit available to supplement cash flows from operations.
Minnesota Mining and Manufacturing Company and Subsidiaries
PART II. Other Information
Item 1. Legal Proceedings
The company and certain of its subsidiaries are named as defendants
in a number of actions, governmental proceedings and claims,
including environmental proceedings and products liability claims
involving products now or formerly manufactured and sold by the
company. In some actions, the claimants seek damages as well as
other relief which, if granted, would require substantial
expenditures. The company has accrued certain liabilities which
represent reasonable estimates of its probable liabilities for these
matters. The company also has recorded receivables for the probable
amount of insurance recoverable with respect to these matters.
Some of these matters raise difficult and complex factual and legal
issues, and are subject to many uncertainties, including, but not
limited to, the facts and circumstances of each particular action,
the jurisdiction and forum in which each action is proceeding and
differences in applicable law. Accordingly, the company is not
always able to estimate the amount of future liabilities with
respect to such matters.
There can be no certainty that the company may not ultimately incur
charges, whether for governmental proceedings and claims, products
liability claims, environmental proceedings or other actions, in
excess of presently established accruals. While such future charges
could have a material adverse impact on the company's net income in
the quarterly period in which they are recorded, the company
believes that such additional charges, if any, would not have a
material adverse effect on the consolidated financial position or
annual results of operations of the company.
Breast Implant Litigation
As of March 31, 1997, the company had been named as a defendant,
often with multiple co-defendants, in 6,754 lawsuits and 128 claims
in various courts, all seeking damages for personal injuries from
allegedly defective breast implants. These claims and lawsuits
purport to represent 22,091 individual claimants. It is not yet
certain how many of these lawsuits and claims involve products
manufactured and sold by the company, as opposed to other
manufacturers. The company entered the business of manufacturing
breast implants in 1977 by purchasing McGhan Medical Corporation.
In 1984, the company sold the business to a corporation that also
was named McGhan Medical Corporation.
The typical claim or lawsuit alleges the individual's breast
implants caused one or more of a wide variety of ailments and local
complications, including, but not limited to, non-specific
autoimmune disease, scleroderma, lupus, rheumatoid arthritis,
fibromyalgia, mixed connective tissue disease, Sjogren's Syndrome,
dermatomyositis, polymyositis and chronic fatigue.
Plaintiffs in these cases typically seek monetary damages, often in
unspecified amounts, and also seek certain types of equitable
relief, including requiring the company to fund the costs associated
with removal of the breast implants.
A number of breast implant claims and lawsuits seek to impose
liability on the company under various theories for personal
injuries allegedly caused by breast implants manufactured and sold
by manufacturers other than the company. These manufacturers
include, but are not limited to, McGhan Medical Corporation and
manufacturers that are no longer in business or that are insolvent,
whose breast implants may or may not have been used in conjunction
with implants manufactured and sold by the company. These claims
raise many difficult and complex factual and legal issues that are
subject to many uncertainties, including the facts and circumstances
of each particular claim, the jurisdiction in which each suit is
brought, and differences in applicable law and insurance coverage.
A number of breast implant lawsuits seek to recover punitive
damages. Any punitive damages that may be awarded against the
company may or may not be covered by certain insurance policies
depending on the language of the insurance policy, applicable law
and agreements with insurers.
In addition to individual suits against the company, a class action
on behalf of all women with breast implants filed against all
manufacturers of such implants has been conditionally certified and
is pending in the United States District Court for the Northern
District of Alabama (the "Court")(DANTE, ET AL., V. DOW CORNING, ET
AL., U.S.D.C., N. Dist., Ala., 92-2589; part of IN RE: SILICONE GEL
BREAST IMPLANT PRODUCT LIABILITY LITIGATION, U.S.D.C., N. Dist.
Ala., MDL 926, U.S.D.C., N. Dist. Ala., CV 92-P-10000-S; now held in
abeyance pending settlement proceedings in the settlement class
action LINDSEY, ET AL., V. DOW CORNING CORPORATION, ET AL.,
U.S.D.C., N. Dist., Ala., CV 94-P-11558-S). Class actions, some of
which have been certified, are pending in various state courts,
including, among others, Louisiana, Florida and Illinois, and in the
British Columbia courts in Canada.
The company also has been served with a purported class action
brought on behalf of children allegedly exposed to silicone in utero
and through breast milk. (FEUER, ET AL., V. MCGHAN, ET AL.,
U.S.D.C., E. Dist. NY, 93-0146.) The suit names all breast implant
manufacturers as defendants and seeks to establish a medical-
monitoring fund.
On December 22, 1995, the Court approved a revised class action
settlement program for resolution of claims seeking damages for
personal injuries from allegedly defective breast implants (the
"Revised Settlement Program"). The Revised Settlement Program is a
revision of a previous settlement pursuant to a Breast Implant
Litigation Settlement Agreement (the "Settlement Agreement") reached
on April 8, 1994, and approved by the Court on September 1, 1994.
The Court ordered that, beginning after November 30, 1995, members
of the plaintiff class may choose to participate in the Revised
Settlement Program or opt out, which would then allow them to
proceed with separate products liability actions.
The Revised Settlement Program as recently supplemented now includes
both foreign and domestic class members with implants manufactured
by certain manufacturer defendants, including Baxter International,
Bristol Meyers-Squibb, the company and McGhan Medical Corporation.
The company's obligations under the Revised Settlement Program are
limited to eligible claimants with implants manufactured by the
company or its predecessors ("3M implants") or manufactured only by
McGhan Medical Corporation after its divestiture from the company on
August 3, 1984 ("Post 8/84 McGhan implants"). With respect to
foreign claimants and claimants with only Post 8/84 McGhan implants
(or only Post 8/84 McGhan implants plus certain other manufacturers'
implants), the benefits are more limited than for domestic claimants
with 3M implants. Post 8/84 McGhan implant benefits are payable by
the company, Union Carbide Corporation and McGhan Medical
Corporation.
In general, the amounts payable to individual current claimants (as
defined in the Court's order) under the Revised Settlement Program,
and the company's obligations to make those payments, will not be
affected by the number of class members electing to opt out of the
Revised Settlement Program or the number of class members making
claims under the Revised Settlement Program. In addition to certain
miscellaneous benefits, the Revised Settlement Program provides for
two compensation options for current claimants with 3M implants.
Under the first option, denominated as Fixed Amount Benefits,
current claimants with 3M implants who satisfy disease criteria
established in the prior Settlement Agreement will receive amounts
ranging from $5,000 to $100,000, depending on disease severity or
disability level; whether the claimant can establish that her
implants have ruptured; and whether the claimant also has had
implants manufactured by Dow Corning. Under the second option,
denominated as Long-Term Benefits, current claimants with 3M
implants who satisfy more restrictive disease and severity criteria
specified under the Revised Settlement Program can receive benefits
ranging from $37,500 to $250,000.
In addition, current claimants with 3M implants are eligible for (a)
a one-time payment of $3,000 upon removal of 3M implants during the
course of the class settlement, and (b) an advance payment of $5,000
against the above referenced benefits upon proof of having 3M
implants and upon waiving or not timely exercising the right to opt
out of the Revised Settlement Program. Current claimants with only
Post 8/84 McGhan implants (or only Post 8/84 McGhan implants plus
certain other manufacturers' implants) are eligible only for
benefits ranging from $10,000 to $50,000.
Eligible participants with 3M implants who did not file current
claims but are able to satisfy the more restrictive disease and
severity criteria during an ongoing period of 15 years will be
eligible for the Long-Term Benefits, subject to certain funding
limitations. Such participants also will be eligible for an advance
payment of $1,000 upon proof of having 3M implants and upon waiving
or not timely exercising the right to opt out of the Revised
Settlement Program. Benefit levels for eligible participants who
are not current claimants and have only Post 8/84 McGhan implants
(or only Post 8/84 McGhan implants plus certain other manufacturers'
implants) or who are current foreign claimants will range from
$10,000 to $50,000. Benefits to foreign registrants other than
current foreign claimants will be developed by the Foreign Claimants
Committee in consultation with the Court.
The company's obligations to fund Long-Term Benefits for eligible
claimants with 3M implants are cancelable if certain provisions of
the Revised Settlement Program are disapproved on appeal. Pending
appeal, the company will pay Long-Term Benefits to eligible
claimants, providing it receives appropriate releases. The
company's obligations to fund any benefits for claimants with only
Post 8/84 McGhan implants are currently suspended pending appeals
and will be canceled if any of certain provisions are disapproved on
appeal. In either event, the other benefits provided under the
Revised Settlement Program would still be payable to any claimant
with 3M implants who elected to participate in the program.
As of the date of this filing, it is still uncertain how many
plaintiffs ultimately will choose to participate in the Revised
Settlement Program, what disease criteria they will satisfy, and
what options they will choose. As a result, the total amount and
timing of the company's prospective payments under the Revised
Settlement Program cannot be determined with precision at this time.
In January 1996, the company paid $125 million into a court-
administered fund as an initial reserve against costs of claims
payable by the company under the Revised Settlement Program (along
with a $5 million administrative assessment).
In the first quarter of 1994, the company took a pre-tax charge of
$35 million ($22 million after tax) in recognition of its then best
estimate of its probable liabilities and associated expenses, net of
the probable amount of insurance recoverable from its carriers. In
the second quarter of 1996, the company increased its estimate of
the minimum probable liabilities and associated expenses to
approximately $991 million. This amount represents the company's
best estimate of the cost and expense of the Revised Settlement
Program and the cost and expense of resolving opt out claims. After
subtracting payments of $548 million as of March 31, 1997 (which
includes the January 1996 payment of $130 million under the Revised
Settlement Program) for defense costs and settlements with litigants
and claimants, the company had accrued liabilities of $443 million.
The company has substantial primary and excess products liability
occurrence insurance coverage and claims-made products liability
insurance coverage, which it believes provide coverage for
substantially all of its current exposure for breast implant claims
and defense costs. Most insurers have alleged reservations of rights
to deny all or part of the coverage for differing reasons, including
each insurer's obligations in relation to the other insurers (i.e.
allocation) and which claims trigger both the various occurrence and
claims-made insurance policies. Some insurers have resolved and
paid, or committed to, their policy obligations. The company
believes the failure of many insurers to voluntarily perform as
promised subjects them to the company's claims for excess liability
and damages for breach of the insurers' obligation of good faith.
On September 22, 1994, three excess coverage occurrence insurers
initiated in the courts of the State of Minnesota a declaratory
judgment action against the company and numerous insurance carriers
seeking adjudication of certain coverage issues and allocation among
insurers. On December 9, 1994, the company initiated an action
against its occurrence insurers in the Texas State Court in and for
Harrison County, seeking a determination of responsibility among the
company's various occurrence insurers with applicable coverages. The
state of Texas has the most implant claims. This action has since
been removed to the U.S. District Court, Eastern District of Texas,
and stayed pending resolution of the litigation in the Minnesota
courts.
The insurers that are parties to these actions generally acknowledge
that they issued products liability insurance to the company and
that breast implant claims are products liability claims. The trial
in Minnesota to resolve the company's insurance coverage and the
financial responsibility of occurrence insurers for breast implant
claims and defense costs began on June 4, 1996 and is continuing in
phases as scheduled by the court.
In mid-October 1995, the occurrence insurers that are parties to the
litigation in Minnesota filed more than 30 motions for summary
judgment or partial summary judgment. The insurers, through these
motions, attempt to shift all or a portion of the responsibility for
those claims the company believes fall within the period of
occurrence-based coverage (before 1986) into the period of claims-
made coverage (from and after 1986). The trial court denied the
insurers' motions, ruling that the key issues of "trigger" and
allocation raised in these motions would be resolved at trial. In
the trial's first phase, the court granted 3M partial declaratory
judgment on the question of when insurance coverage is "triggered."
The court also granted the insurers' motion for partial declaratory
judgment on the question of the allocation method to be applied in
the case. The trial will continue with further developments
expected on the allocation issue, including the specific application
of the court-selected method of allocation to particular policies.
If the occurrence insurers ultimately prevail in this insurance
litigation, the company could be effectively deprived of significant
insurance coverage for breast implant claims, the amount of which is
not presently determinable. (See discussion of the accrued
receivables for insurance recoveries below.)
The company believes it ultimately will prevail in this insurance
litigation. The company's belief is based on an analysis of its
insurance policies; court decisions on similar issues; reimbursement
by insurers for these types of claims; and consultation with outside
counsel who are experts in insurance coverage matters.
As of March 31, 1997, the company had accrued receivables for
insurance recoveries of $860 million. Various factors could affect
the timing and amount of proceeds to be received under the company's
various insurance policies, including (i) the timing of payments
made in settlement of claims, (ii) the outcome of occurrence
insurance litigation in the courts of Minnesota (as discussed above)
and Texas, (iii) potential arbitration with claims-made insurers,
(iv) delays in payment by insurers and (v) the extent to which
insurers may become insolvent in the future. There can be no
absolute assurance that the company will collect all amounts accrued
as being probable of recovery from its insurers.
The company's current estimate of the probable liabilities,
associated expenses and probable insurance recoveries related to the
breast implant claims is based on the facts and circumstances
existing at this time. New developments may occur that could affect
the company's estimates of probable liabilities (including
associated expenses) and the probable amount of insurance
recoveries. These developments include, but are not limited to, (i)
the number of plaintiffs who elect to opt out and pursue individual
claims against the company, (ii) the success of and costs to the
company in defending such opt-out claims, including claims involving
breast implants not manufactured or sold by the company, (iii) the
outcome of the occurrence insurance litigation in the courts of
Minnesota and Texas, and (iv) the outcome of potential arbitration
with claims-made insurers.
The company cannot determine the impact of these potential
developments on the current estimate of probable liabilities
(including associated expenses) and the probable amount of insurance
recoveries. Accordingly, the company is not able to estimate its
potential future liabilities beyond the current estimate of probable
liabilities. As new developments occur, the estimates may be
revised, or additional charges may be necessary to reflect the
impact of these developments on the costs to the company of
resolving breast implant litigation and claims. While such
revisions or additional future charges could have a material adverse
impact on the company's net income in the quarterly period in which
they are recorded, the company believes that such revisions or
additional charges, if any, would not have a material adverse effect
on the consolidated financial position or annual results of
operations of the company.
The company conducts ongoing reviews, assisted by outside counsel,
to determine the adequacy and extent of insurance coverage provided
by its occurrence and claims-made insurers. The company believes,
based on these ongoing reviews and the bases described in the fourth
preceding paragraph, that the collectible coverage provided by its
applicable insurance policies is sufficient to cover substantially
all of its current exposure for breast implant claims and defense
costs. Based on the availability of this insurance coverage, the
company believes that its uninsured financial exposure has not
materially changed since the first quarter of 1994. Therefore, no
recognition of additional charges has been made.
Environmental Matters
The company also is involved in a number of environmental
proceedings by governmental agencies and by private parties
asserting liability for past waste disposal and other alleged
environmental damage. The company conducts ongoing investigations,
assisted by environmental consultants, to determine accruals for the
probable, estimable costs of remediation. The remediation accruals
are reviewed each quarter and changes are made as appropriate.
Item 6. Exhibits and Reports on Form 8-K
(a) The following documents are filed as exhibits to this
Report.
(11) A statement regarding the computation of per share
earnings. Page 21.
(12) A statement regarding the calculation of ratio of
earnings to fixed charges. Page 22.
(15) A letter from the company's independent auditors
regarding unaudited interim financial statements.
Page 23.
(27) Financial data schedule (EDGAR filing only).
None of the other items contained in Part II of this Form 10-Q are
applicable to the company for the quarter ended March 31, 1997.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
MINNESOTA MINING AND MANUFACTURING COMPANY
(Registrant)
Date: April 22, 1997
/s/ Giulio Agostini
Giulio Agostini, Senior Vice President and
Chief Financial Officer
(Mr. Agostini is the Principal Financial
and Accounting Officer and has been duly
authorized to sign on behalf of the
registrant.)
EXHIBIT 11
MINNESOTA MINING AND MANUFACTURING COMPANY AND SUBSIDIARIES
EARNINGS PER SHARE OF COMMON STOCK
(Unaudited)
Three months ended
March 31
1997 1996
------- -------
(Millions)
Net income $410 $362
- --------------------------------------------------------
Primary earnings per share:
Net Income $.99 $.87
Weighted average number of
common shares outstanding 416,605,836 418,545,428
- --------------------------------------------------------
Fully diluted earnings
per share: (1)
Net Income $.97 $.85
Weighted average number of
common shares outstanding 416,605,836 418,545,428
Common equivalent shares 6,471,512 6,082,097
----------- -----------
Average number of common
and common equivalent
shares outstanding 423,077,348 424,627,525
- ---------------------------------------------------------
Primary earnings per share is computed by dividing net income by the
weighted average number of common shares outstanding for each period.
The calculation excludes the effect of common equivalent shares
resulting from stock options using the treasury stock method as the
effect would not be material.
Fully diluted earnings per share is computed based on the weighted
average number of common shares and common equivalent shares
outstanding for each period.
(1) This calculation is submitted in accordance with Regulation S-K
Item 601(b)(11) although not required by APB Opinion No. 15 because it
results in dilution of less than 3%.
EXHIBIT 12
MINNESOTA MINING AND MANUFACTURING COMPANY AND SUBSIDIARIES
CALCULATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Dollars in millions)
(Unaudited)
Three Months
Ended
March 31, Year Year Year Year Year
1997 1996 1995 1994 1993 1992
EARNINGS ------- ------- ------- ------- ------- -------
Income from continuing
operations before
income taxes and
minority interest $677 $2,479 $2,168 $2,011 $1,851 $1,779
Add:
Interest on debt 23 79 102 70 39 61
Interest component of the
ESOP benefit expense 8 34 37 39 41 42
Portion of rent under
operating leases
representative of the
interest component 11 46 51 46 44 44
Less:
Equity in undistributed
income of 20-50% owned
companies 1 -- 1 2 -- (1)
----- ------- ------- ------- ------- -------
TOTAL EARNINGS AVAILABLE
FOR FIXED CHARGES $718 $2,638 $2,357 $2,164 $1,975 $1,927
FIXED CHARGES
Interest on debt 23 79 102 70 39 61
Interest component of the
ESOP benefit expense 8 34 37 39 41 42
Portion of rent under
operating leases
representative of the
interest component 11 46 51 46 44 44
---- ------ ------ ------ ------ ------
TOTAL FIXED CHARGES $ 42 $ 159 $ 190 $ 155 $ 124 $ 147
RATIO OF EARNINGS TO
FIXED CHARGES 17.10 16.59 12.41 13.96 15.93 13.11
EXHIBIT 15
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
We are aware that our report dated April 22, 1997 on our reviews of
interim condensed consolidated financial information of Minnesota
Mining and Manufacturing Company and Subsidiaries (the Company) for
the three-month periods ended March 31, 1997 and 1996, and included in
the Company's Form 10-Q for the quarter ended March 31, 1997, is
incorporated by reference in the Company's registration statements on
Form S-8 (Registration Nos. 2-78422, 33-14791, 33-48690, 33-49842, 33-
58763 and 33-58767), and Form S-3 (Registration No. 33-48089).
Pursuant to Rule 436(c), under the Securities Act of 1933, this report
should not be considered a part of the registration statements
prepared or certified by us within the meaning of Sections 7 and 11 of
that Act.
/s/ COOPERS & LYBRAND L.L.P.
COOPERS & LYBRAND L.L.P.
St. Paul, Minnesota
April 22, 1997
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM
THE CONSOLIDATED FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH CONSOLIDATED FINANCIAL STATEMENTS AND NOTES.
</LEGEND>
<MULTIPLIER> 1,000,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-END> MAR-31-1997
<CASH> 373
<SECURITIES> 163
<RECEIVABLES> 2,612
<ALLOWANCES> 0
<INVENTORY> 2,304
<CURRENT-ASSETS> 6,437
<PP&E> 11,985
<DEPRECIATION> 7,159
<TOTAL-ASSETS> 13,296
<CURRENT-LIABILITIES> 3,685
<BONDS> 831
<COMMON> 296
0
0
<OTHER-SE> 5,940
<TOTAL-LIABILITY-AND-EQUITY> 13,296
<SALES> 3,714
<TOTAL-REVENUES> 3,714
<CGS> 2,089
<TOTAL-COSTS> 2,089
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 23
<INCOME-PRETAX> 677
<INCOME-TAX> 244
<INCOME-CONTINUING> 410
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 410
<EPS-PRIMARY> .99
<EPS-DILUTED> .99
</TABLE>
